PCE Dispertab and Rozlytrek

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. According to the prescribing information, administration of entrectinib with a moderate CYP450 3A4 inhibitor is predicted to increase entrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 2.9- and 3-fold, respectively. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia. MANAGEMENT: Concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided when possible. If coadministration is necessary, the manufacturer recommends that the dosage of entrectinib be reduced to 200 mg once daily for adults and pediatric patients (12 years and older) with a body surface area greater than 1.5 m2. Following discontinuation of a moderate CYP450 3A4 inhibitor for 3 to 5 elimination half-lives, the entrectinib dosage that was taken prior to initiating the CYP450 3A4 inhibitor may be resumed. For pediatric patients with a body surface area of 1.5 m2 or less, concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided. References "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.

GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. According to the prescribing information, administration of entrectinib with a moderate CYP450 3A4 inhibitor is predicted to increase entrectinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 2.9- and 3-fold, respectively. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia.

MANAGEMENT: Concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided when possible. If coadministration is necessary, the manufacturer recommends that the dosage of entrectinib be reduced to 200 mg once daily for adults and pediatric patients (12 years and older) with a body surface area greater than 1.5 m2. Following discontinuation of a moderate CYP450 3A4 inhibitor for 3 to 5 elimination half-lives, the entrectinib dosage that was taken prior to initiating the CYP450 3A4 inhibitor may be resumed. For pediatric patients with a body surface area of 1.5 m2 or less, concomitant use of entrectinib with moderate CYP450 3A4 inhibitors should be avoided.

PCE Dispertab

Generic Name: erythromycin

Brand name: EES. Granules, EES-400 Filmtab, EryPed 200, EryPed 400, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab, PCE Dispertab, E. E. S, EryPed, Erythrocin, Erythromycin Filmtabs, Erythromycin Lactobionate - IV

Synonyms: PCE Dispertab (Oral), PCE, PCE (Oral)

What is PCE Dispertab?

Rozlytrek

Generic Name: entrectinib

Brand name: Rozlytrek

Synonyms: n.a.

What is Rozlytrek?